Barclays PLC Aadi Bioscience, Inc. Transaction History

Barclays PLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$1.46 - $2.31 $16,568 - $26,213	-11,348 Reduced 99.93%	8 $0
Q1 2024 May 15, 2024	SELL	$1.59 - $2.44 $17,338 - $26,608	-10,905 Reduced 48.99%	11,356 $27,000
Q4 2023 Feb 15, 2024	BUY	$1.97 - $5.41 $38,284 - $105,137	19,434 Added 687.44%	22,261 $45,000
Q3 2023 Nov 07, 2023	SELL	$4.84 - $7.13 $1,940 - $2,859	-401 Reduced 12.42%	2,827 $14,000
Q2 2023 Aug 03, 2023	SELL	$6.84 - $8.56 $27,961 - $34,993	-4,088 Reduced 55.88%	3,228 $22,000
Q1 2023 May 04, 2023	BUY	$6.85 - $13.0 $23,481 - $44,564	3,428 Added 88.17%	7,316 $53,000
Q4 2022 Feb 13, 2023	BUY	$11.99 - $14.5 $39,255 - $47,473	3,274 Added 533.22%	3,888 $50,000
Q3 2022 Nov 03, 2022	SELL	$12.03 - $14.22 $3,921 - $4,635	-326 Reduced 34.68%	614 $9,000
Q2 2022 Aug 12, 2022	BUY	$11.57 - $17.92 $10,875 - $16,844	940 New	940 $12,000

12.6M

23.8K

Ticker AADI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 21,016,800
Market Cap $48.3M
Description
Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, ...

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

Stay updated on Barclays PLC with notifications on news.